1.         Warskulat U, Heller-Stilb B, Oermann E, Zilles K, Haas H, Lang F, et al. Phenotype of the taurine transporter knockout mouse. Methods Enzymol. 2007;428:439–458. [PubMed] [Google Scholar]

2.         Ito T, Kimura Y, Uozumi Y, Takai M, Muraoka S, Matsuda T, et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol. 2008;44:927–937. [PubMed] [Google Scholar]

3.         Ito T, Oishi S, Takai M, Kimura Y, Uozumi Y, Fujio Y, et al. Cardiac and skeletal muscle abnormality in taurine transporter-knockout mice. J Biomed Sci. 2010;17:S20. [PMC free article] [PubMed] [Google Scholar]

4.         Lötsch J, Hummel T, Warskulat U, Coste O, Häussinger D, Geisslinger G, et al. Congenital taurine deficiency in mice is associated with reduced sensitivity to nociceptive chemical stimulation. Neuroscience. 2014;259:63–70. [PubMed] [Google Scholar]

5.         Schaffer SW, Shimada K, Jong CJ, Ito T, Azuma J, Takahashi K. Effect of taurine and potential interactions with caffeine on cardiovascular function. Amino Acids. 2014;6:1147–1157. [PubMed] [Google Scholar]

6.         Barbiera A et al. “Taurine Attenuates Catabolic Processes Related to the Onset of Sarcopenia.” Int J Mol Sci.2020

7.         Doss HM et al. “Taurine Supplementation Inhibits the Expression of Atrogin-1 and MURF-1, Protein Degradation Marker Genes, in Skeletal Muscle of C26-Induced Cachexia Mouse Model.” Adv Exp Med Biol. 2022; 1370:129-136.

8.         Singh P et al. Taurine deficiency as a driver of aging. 2023 Jun 9;380(6649):eabn9257. doi: 10.1126/science.abn9257. Epub 2023 Jun 9.

9.         Garnier S, Harakalova M, Weiss S, et al.: Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. Eur Heart J. England; 2021;42(20):2000–2011. 10.1093/eurheartj/ehab030 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10.       6. Tadros R, Francis C, Xu X, et al.: Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat Genet. 2021;53(2):128–134. 10.1038/s41588-020-00762-2 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11.       7. Aguet F, Barbeira AN, Bonazzola R, et al.: The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369(6509):1318–1330. 10.1126/science.aaz1776 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12.       8. Ansar M, Ranza E, Shetty M, et al.: Taurine treatment of retinal degeneration and cardiomyopathy in a consanguineous family with SLC6A6 taurine transporter deficiency. Hum Mol Genet. 2020;29(4):618–623. 10.1093/hmg/ddz303 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13.       9. Schaffer SW, Shimada-Takaura K, Jong CJ, et al.: Impaired energy metabolism of the taurine-deficient heart. Amino Acids. 2016;48(2):549–58. 10.1007/s00726-015-2110-2 [PubMed] [CrossRef] [Google Scholar]

14.       10. Pion PD, Kittleson MD, Rogers QR, et al.: Myocardial failure in cats associated with low plasma taurine: A reversible cardiomyopathy. Science. 1987;237(4816):764–768. 10.1126/science.3616607 [PubMed] [CrossRef] [Google Scholar]

15.       11. Pion PD, Kittleson MD, Thomas WP, et al.: Response of cats with dilated cardiomyopathy to taurine supplementation. J Am Vet Med Assoc. 1992;201(2):275–284. [PubMed] [Google Scholar]

16.       12. Moise NS, Pacioretty LM, Kallfelz FA, et al.: Dietary taurine deficiency and dilated cardiomyopathy in the fox. Am Heart J. 1991;121(2 Pt 1):541–547. 10.1016/0002-8703(91)90724-v [PubMed] [CrossRef] [Google Scholar]

17.       13. Keith ME, Ball A, Jeejeebhoy KN, et al.: Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. Can J Cardiol. 2001;17(4):449–458. [PubMed] [Google Scholar]

18.       14. Kittleson MD, Keene B, Pion PD, et al.: Results of the multicenter spaniel trial (MUST): taurine- and carnitine-responsive dilated cardiomyopathy in American cocker spaniels with decreased plasma taurine concentration. J Vet Intern Med. 1997;11(4):204–211. 10.1111/j.1939-1676.1997.tb00092.x [PubMed] [CrossRef] [Google Scholar]

19.       15. Wells GA, Shea B, O’Connell D, et al.: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Reference Source [Google Scholar]

20.       16. Trafford AM, Parisi R, Kontopantelis E, et al.: Association of Psoriasis with the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;155(12):1390–1403. 10.1001/jamadermatol.2019.3056 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21.       17. Averin E: Use of taurine during rehabilitation after cardiac surgery. Adv Exp Med Biol. United States;2015;803:637–649. 10.1007/978-3-319-15126-7_51 [PubMed] [CrossRef] [Google Scholar]

22.       18. Azuma J, Sawamura A, Awata N, et al.: Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol. United States;1985;8(5):276–282. 10.1002/clc.4960080507 [PubMed] [CrossRef] [Google Scholar]

23.       19. Jeejeebhoy F, Keith M, Freeman M, et al.: Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. United States;2002;143(6):1092–1100. 10.1067/mhj.2002.121927 [PubMed] [CrossRef] [Google Scholar]

24.       20. Shiohira S, Komatsu M, Okazaki M, et al.: Effect of Taurine on Hemodiafiltration in Patients With Chronic Heart Failure. Ther Apher Dial. Australia;2016;20(1):20–26. 10.1111/1744-9987.12330 [PubMed] [CrossRef] [Google Scholar]

25.       21. Azuma J, Sawamura A, Awata N: Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J. Japan;1992;56(1):95–99. 10.1253/jcj.56.95 [PubMed] [CrossRef] [Google Scholar]

26.       22. Beyranvand MR, Khalafi MK, Roshan VD, et al.: Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol. Netherlands;2011;57(3):333–337. 10.1016/j.jjcc.2011.01.007 [PubMed] [CrossRef] [Google Scholar]

27.       23. Ahmadian M, Dabidi Roshan V, Ashourpore E: Taurine Supplementation Improves Functional Capacity, Myocardial Oxygen Consumption, and Electrical Activity in Heart Failure. J Diet Suppl. England;2017;14(4):422–432. 10.1080/19390211.2016.1267059 [PubMed] [CrossRef] [Google Scholar]

28.       24. Ahmadian M, Roshan VD, Aslani E, et al.: Taurine supplementation has anti-atherogenic and anti-inflammatory effects before and after incremental exercise in heart failure. Ther Adv Cardiovasc Dis. 2017;11(7):185–194. 10.1177/1753944717711138 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29.       25. Azuma J: Long-term effect of taurine in congestive heart failure: preliminary report. Heart Failure Research with Taurine Group. Adv Exp Med Biol. United States;1994;359:425–433. 10.1007/978-1-4899-1471-2_46 [PubMed] [CrossRef] [Google Scholar]

30.       26. Azuma J, Hasegawa H, Sawamura A, et al.: Taurine for treatment of congestive heart failure. Int J Cardiol. Netherlands;1982;2(2):303–304. 10.1016/0167-5273(82)90052-3 [PubMed] [CrossRef] [Google Scholar]

31.       27. Azab SR, Sabri NA, Khorshid H, et al.: Evaluation of the effect of taurine supplementation in chronic heart failure patients; a new study on old amino acid. Eur J Heart Fail. 2016;Abstracts:P228. [Google Scholar]